Seroprevalence of measles, rubella, and mumps antibodies in Catalonia, Spain: results of a cross-sectional study - PubMed (original) (raw)

Seroprevalence of measles, rubella, and mumps antibodies in Catalonia, Spain: results of a cross-sectional study

A Domínguez et al. Eur J Clin Microbiol Infect Dis. 2006 May.

Abstract

Determination of antibody levels against vaccine-preventable diseases is of great value to assess immunization programmes. The objective of this study was to determine the prevalence of measles, rubella, and mumps antibodies in representative samples of the child and adult population of Catalonia and compare the findings to those obtained in 1996. A representative sample of the child and adult (>or=15 years) population of Catalonia was studied. Enzyme-linked immunosorbent assay techniques were used to determine the presence of antibodies. Equivocal results for antibodies against measles and rubella were tested using an immunofluorescence technique. To compare proportions, the chi-square test and the Fisher's exact test were used. Statistical significance was set at 0.05. Adjusted odds ratios were calculated using multiple logistic regression analysis. Samples from 2,619 people were analyzed. The global prevalence of antibodies was 98.3% for measles, 91.1% for mumps, and 98.1% for rubella. The prevalence of rubella antibodies was higher in women than in men (98.8 vs. 97.2%, respectively). Compared with the results obtained in the 1996 seroprevalence study, only the prevalence of rubella antibodies showed a statistically significant increase in men (97.2 vs. 94.6%; p=0.002) and, in particular, in women (98.8 vs. 95.3%; p<0.001). The low prevalence of susceptible subjects has already led to the elimination of indigenous measles in Catalonia and should allow the elimination of indigenous rubella by 2005. The level of antibodies necessary to interrupt the transmission of mumps has still not been reached in all age groups.

PubMed Disclaimer

Similar articles

• [Seroprevalence of antibodies against measles, rubella, mumps and varicella among school children in Madrid].
  Gil Miguel A, Astasio Arbiza P, Ortega Molina P, Domínguez Rojas V, González López A. Gil Miguel A, et al. An Esp Pediatr. 1999 May;50(5):459-62. An Esp Pediatr. 1999. PMID: 10394183 Spanish.
• Seroprevalence of measles, mumps and rubella antibodies in Luxembourg: results from a national cross-sectional study.
  Mossong J, Putz L, Schneider F. Mossong J, et al. Epidemiol Infect. 2004 Jan;132(1):11-8. doi: 10.1017/s0950268803001584. Epidemiol Infect. 2004. PMID: 14979584 Free PMC article.
• Prevalence of anti-rubella, anti-measles and anti-mumps IgG antibodies in neonates and pregnant women in Catalonia (Spain) in 2013: susceptibility to measles increased from 2003 to 2013.
  Plans P, de Ory F, Campins M, Álvarez E, Payà T, Guisasola E, Compte C, Vellbé K, Sánchez C, Lozano MJ, Aran I, Bonmatí A, Carreras R, Jané M, Cabero L. Plans P, et al. Eur J Clin Microbiol Infect Dis. 2015 Jun;34(6):1161-71. doi: 10.1007/s10096-015-2339-4. Epub 2015 Feb 10. Eur J Clin Microbiol Infect Dis. 2015. PMID: 25666082
• [Sero-epidemiologic study of measles, rubella and mumps in the infantile population of Salamanca].
  Sáenz González MC, Núñez Mateos JC, Rodrigo Sánchez N, Martín Sánchez AM. Sáenz González MC, et al. An Esp Pediatr. 1992 Apr;36(4):293-7. An Esp Pediatr. 1992. PMID: 1605414 Review. Spanish.
• [Measles, pertussis, rubella and mumps completeness of reporting. Literature review of estimates for industrialized countries].
  Trottier H, Carabin H, Philippe P. Trottier H, et al. Rev Epidemiol Sante Publique. 2006 Feb;54(1):27-39. doi: 10.1016/s0398-7620(06)76692-5. Rev Epidemiol Sante Publique. 2006. PMID: 16609635 Review. French.

Cited by

• Immune Cells, Gut Microbiota, and Vaccines: A Gender Perspective.
  Rio P, Caldarelli M, Chiantore M, Ocarino F, Candelli M, Gasbarrini A, Gambassi G, Cianci R. Rio P, et al. Cells. 2024 Mar 17;13(6):526. doi: 10.3390/cells13060526. Cells. 2024. PMID: 38534370 Free PMC article. Review.
• Potential immunological effects of gender-affirming hormone therapy in transgender people - an unexplored area of research.
  White AA, Lin A, Bickendorf X, Cavve BS, Moore JK, Siafarikas A, Strickland DH, Leffler J. White AA, et al. Ther Adv Endocrinol Metab. 2022 Dec 10;13:20420188221139612. doi: 10.1177/20420188221139612. eCollection 2022. Ther Adv Endocrinol Metab. 2022. PMID: 36533187 Free PMC article. Review.
• SARS-CoV-2 spike IgG titres up to 137 days following Comirnaty mRNA COVID-19 vaccination, Israel, February to May 2021.
  Patalon T, Ben Moshe S, Peretz A, Neuberger A, Schreiber L, Lazar R, Supino-Rosin L, Perez G, Mizrahi-Reuveni M, Gazit S. Patalon T, et al. Euro Surveill. 2022 Oct;27(40):2100703. doi: 10.2807/1560-7917.ES.2022.27.40.2100703. Euro Surveill. 2022. PMID: 36205168 Free PMC article.
• The Concordance between Mumps and Rubella Sero-Positivity among the Israeli Population in 2015.
  Bassal R, Shohat T, Levin T, Pando R, Shinar E, Amichay D, Barak M, Ben-Dor A, Bar-Haim A, Mendelson E, Cohen D, Keinan-Boker L, Indenbaum V. Bassal R, et al. Vaccines (Basel). 2022 Jun 22;10(7):996. doi: 10.3390/vaccines10070996. Vaccines (Basel). 2022. PMID: 35891160 Free PMC article.
• Gender differences in measles incidence rates in a multi-year, pooled analysis, based on national data from seven high income countries.
  Green MS, Schwartz N, Peer V. Green MS, et al. BMC Infect Dis. 2022 Apr 11;22(1):358. doi: 10.1186/s12879-022-07340-3. BMC Infect Dis. 2022. PMID: 35410143 Free PMC article.

References

1. 1. Am J Epidemiol. 2000 Jun 1;151(11):1039-48; discussion 1049-52 - PubMed
2. 1. Trop Med Int Health. 2002 Jun;7(6):512-7 - PubMed
3. 1. Vaccine. 1999 Feb 12;17(6):530-4 - PubMed
4. 1. Acta Med Port. 1999 Apr-Jun;12(4-6):155-60 - PubMed
5. 1. Epidemiol Infect. 2003 Aug;131(1):691-701 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Medical

  • MedlinePlus Health Information